Why the biggest lung clots are often the ones that don't hurt
A pulmonary embolism is usually a clot that breaks off in a leg vein and lodges in a lung artery. You might expect bigger clots to cause worse pain. Often the reverse holds: large central clots can be painless because backup circulation keeps lung tissue alive, while small ones at the edges cause sharp pain.
Roughly nine in ten emboli start as deep vein thrombosis above the knee. Doctors group the leg clot and the lung blockage together as one continuum, venous thromboembolism. A small share of cases involve air, fat or amniotic fluid instead of blood. The classic framework for why clots form is Virchow's triad: sluggish blood flow, damage to vessel walls, and blood that clots too readily. Immobility after surgery, travel lasting over four hours, pregnancy, cancer, oestrogen-containing drugs and inherited conditions such as factor V Leiden all push one or more of those levers.
The size paradox shapes diagnosis. Small emboli lodge far out in the lung where there is no backup supply, causing painful tissue death and small effusions but little breathlessness. Large ones stick centrally, bringing low oxygen, low blood pressure, a racing heart and fainting, yet frequently no pain. The textbook trio of pleuritic pain, breathlessness and fast heartbeat probably comes from a clot that fragments into both sizes. As a result, small clots get missed because pain is the only sign, and big ones get missed because they mimic other illnesses.
Since symptoms overlap with many chest complaints, doctors lean on scoring systems. Philip Steven Wells created a rule for leg clots in 1995 and one for lung clots in 1998, revised in 2000, and several versions now compete. In low-risk patients a D-dimer blood test can rule the condition out; otherwise CT pulmonary angiography is the preferred scan. Using any validated rule is linked with fewer recurrences. A clot registers in fewer than 1% of fainting cases, yet accounts for about 15% of sudden deaths.
Europe sees about 430,000 cases a year, and the United States between 300,000 and 600,000, contributing to at least 40,000 deaths. Men and women are affected at similar rates, and risk climbs with age. Standard treatment uses anticoagulants such as heparin, warfarin or newer oral drugs, generally for at least three months, with clot-dissolving medicine or surgery reserved for severe cases.
Source: Pulmonary embolism
